Besremi passes cancer drug reimbursement panel in 2nd try
PharmaEssentia's polycythemia vera (PV) drug Besremi (rofeginterferon alfa-2b), which is rechallenging for insurance coverage, has passed the first gateway of the Cancer Disease Review Committee (CDRC). HK inno.N's application for a new benefit for …